Affinivax and Astellas Pharma have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus). The partnership will utilize Affinivax’s vaccine technology platform, Multiple Antigen Presenting System (MAPS), to advance a vaccine targeted to prevent and reduce the spread of pneumococcal disease. Astellas will lead and fund the development program and will obtain worldwide rights to commercialize the MAPS vacci...